Last $66.05 USD
Change Today -1.67 / -2.47%
Volume 185.1K
PCRX On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $83.41
52 Week Low
05/8/13 - $24.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

pacira pharmaceuticals inc (PCRX) Related Businessweek News

No Related Businessweek News Found

pacira pharmaceuticals inc (PCRX) Details

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company commercializes EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase III clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate, an oncology preclinical candidate, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

308 Employees
Last Reported Date: 02/25/14
Founded in 2006

pacira pharmaceuticals inc (PCRX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $693.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $418.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2012.

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals Seeks Acquisitions

Pacira Pharmaceuticals, Inc. (NasdaqGS:PCRX) is offering 1.6 million shares of its common stock. Pacira Pharmaceuticals estimate net proceeds from this offering will be approximately $96.0 million. Pacira Pharmaceuticals intends to use net proceeds from this offering to fund the continued commercialization of EXPAREL, the development of additional indications for EXPAREL, internal product development programs and for general corporate purposes, including working capital. Pacira Pharmaceuticals may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products.

Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity

Pacira Pharmaceuticals, Inc. announced entering into a strategic co-production partnership with Patheon to manufacture and package EXPAREL(R) (bupivacaine liposome injectable suspension) at Patheon's facility in Swindon, United Kingdom. Under the co-production partnership agreements, Pacira and Patheon will collaborate to construct dedicated EXPAREL manufacturing suites in Patheon's specialty sterile manufacturing facility in Swindon. The first additional EXPAREL manufacturing suite at Patheon, which is expected to come online in two to three years' time, will be designed to mirror the recently approved Suite C manufacturing facility at the Pacira Science Center Campus in San Diego, providing, at scale, approximately $300 million of additional product manufacturing capacity, or an aggregate $700 million worth of overall production capacity for EXPAREL. The design and production scale of the second additional manufacturing suite will be determined at a future date. Patheon will be responsible for the construction of the dedicated manufacturing suites, installation and validation of the manufacturing equipment and the commercial manufacture of EXPAREL. Pacira will oversee the design and purchase of the dedicated EXPAREL manufacturing equipment to be installed in the Patheon facility, lead the technical transfer of the manufacturing process and govern, with on-site and other personnel, the oversight and optimization of the proprietary DepoFoam(R) -based manufacturing process.

Pacira Pharmaceuticals, Inc. Announces Additional Phase 3 Data

Pacira Pharmaceuticals, Inc. announced additional Phase 3 data supporting the efficacy and safety of EXPAREL(R) (bupivacaine liposome injectable suspension) to achieve a femoral nerve block in patients undergoing total knee arthroplasty. The Company previously announced results of the primary efficacy endpoint, a statistically significant reduction in cumulative pain scores over 72 hours compared to placebo (P<0.0001). Secondary endpoints presented at the 39(th) Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA) found that a higher percentage of patients who received EXPAREL were pain-free, consumed fewer opioids and reported higher satisfaction with their pain control. This randomized, double blind, placebo controlled study evaluated 278 patients who received either a femoral nerve block with EXPAREL or a placebo. A femoral nerve block provides pain control for the anterior (front) of the knee; in this trial there was no pain medication provided at the time of surgery for the posterior (back) of the knee, which explains the lack of a significant difference in time to first opioid rescue between the two study groups. In addition to pain scores through 72 hours, investigators also measured total opioid consumption through 72 hours, time to first opioid rescue, patient satisfaction with pain control and safety. The key findings are summarized below: A 24% reduction in total opioid use in the EXPAREL group (P<0.05); there was no significant difference between groups in the time to first opioid rescue. A greater number of patients who were "extremely satisfied" with pain control in the EXPAREL group vs. placebo group at day 7 (55% vs. 43%) and day 30 (65% vs. 50%). A statistically significantly higher percentage of "pain-free" patients in the EXPAREL group (50% vs. 40% for placebo group at 60 hours; [P<0.05]). Safety was comparable between the EXPAREL and placebo groups, with similar numbers of patients displaying a normal ability to do a 20-meter walk test and similar physician satisfaction with return of motor function. Five additional studies evaluating the use of EXPAREL in transversus abdominis plane infiltration and nerve block will also be presented at the ASRA meeting.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $66.05 USD -1.67

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexza Pharmaceuticals Inc $4.13 USD +0.03
Durect Corp $1.31 USD +0.02
Flamel Technologies SA $11.26 USD +0.66
Inovio Pharmaceuticals Inc $2.52 USD -0.15
Nektar Therapeutics $10.97 USD -0.075
View Industry Companies

Industry Analysis


Industry Average

Valuation PCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.9x
Price/Book 53.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.2x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at